Quantification of fetal drug exposure remains challenging since sampling from the placenta
or fetus during pregnancy is too invasive. Currently existing in vivo (eg, cord blood sampling) …

Addressing significant medical challenges arising from tissue damage and organ failure, the
field of tissue engineering has evolved to provide revolutionary approaches for regenerating …

Recent FDA modernization act 2.0 has led to increasing industrial R&D investment in
advanced in vitro 3D models such as organoids, spheroids, organ-on-chips, 3D bioprinting …

Liver is responsible for the metabolization processes of up to 90% of compounds and toxins
in the body. Therefore liver-on-a-chip systems, as an in vitro promising cell culture platform …

The liver, as the body's primary organ for maintaining internal balance, is composed of
numerous hexagonal liver lobules, each sharing a uniform architectural framework. These …

Drug discovery is an expensive, long, and complex process, usually with a high degree of
uncertainty. In order to improve the efficiency of drug development, effective methods are …

Metabolic dysfunction-associated fatty liver disease (MASLD) presents a growing global
health challenge with limited therapeutic choices. This review delves into the array of ex vivo …

The liver is the largest internal organ of the human body. It has a complex structure and
function and plays a vital role in drug metabolism. In recent decades, extensive research has …

Liver diseases account for a significant number of deaths worldwide, being largely attributed
to complications of cirrhosis and hepatocellular carcinoma (1). Still, treatment options for …

Drug-induced liver injury (DILI) refers to drug-mediated damage to the structure and function
of the liver, ranging from mild elevation of liver enzymes to severe hepatic insufficiency, and …